KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Capital Leases (2019)

Historic Capital Leases for Adaptive Biotechnologies (ADPT) over the last 1 years, with Q4 2019 value amounting to $36.6 million.

  • Adaptive Biotechnologies' Capital Leases changed N/A to $36.6 million in Q4 2019 from the same period last year, while for Dec 2019 it was $36.6 million, marking a year-over-year change of. This contributed to the annual value of $36.6 million for FY2019, which is N/A changed from last year.
  • Per Adaptive Biotechnologies' latest filing, its Capital Leases stood at $36.6 million for Q4 2019.
  • Adaptive Biotechnologies' 5-year Capital Leases high stood at $36.6 million for Q4 2019, and its period low was $23.4 million during Q3 2019.